Metastatic Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Responding to Nivolumab Plus Ipilimumab

Overview

Journal IJU Case Rep

Date 2021 Sep 9

PMID 34497997

Citations 8

Authors

Hirotaka Fuchizawa

Toshiki Kijima

Atsuko Takada-Owada

Yoji Nagashima

Akihito Okazaki

Megumi Yokoyama

Daisaku Nishihara

Kazuyuki Ishida

Takao Kamai

Affiliations

Soon will be listed here.

Abstract

Introduction: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity.

Case Presentation: We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of multiple osseous metastases after undergoing cytoreductive nephrectomy followed by combination immunotherapy (ipilimumab plus nivolumab). Immunohistochemical analyses of the primary tumor revealed the presence of the tumor-infiltrating immune cells, including activated CD8 T cells and PD-L1 expression, suggesting an immunologically hot tumor.

Conclusion: Combination immunotherapy was a viable treatment option for this disease. Immunohistochemical analyses of the tumor-infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors against rare renal cancers.

Citing Articles

Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell Carcinoma.

Makker S, Shah N, Carlo M, Kuo F, Hakimi A, Chen Y Curr Oncol. 2025; 32(2).

PMID: 39996894 PMC: 11854795. DOI: 10.3390/curroncol32020094.

Early recurrence and extensive retroperitoneal metastasis after surgery for high‑grade mucinous tubular and spindle cell carcinoma: A case report and literature review.

Ma X, Xu J, Ye X, Yang F, Wang Z, Feng J Oncol Lett. 2024; 28(4):467.

PMID: 39119228 PMC: 11306991. DOI: 10.3892/ol.2024.14600.

Long-time Survival of a Renal Transplant Recipient With Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report.

Kobari Y, Yoshida K, Minoda R, Fukuda H, Hata K, Unagami K In Vivo. 2023; 37(3):1394-1398.

PMID: 37103106 PMC: 10188042. DOI: 10.21873/invivo.13223.

[Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis].

Shen Q, Liu Y, He Q Beijing Da Xue Xue Bao Yi Xue Ban. 2023; 55(2):276-282.

PMID: 37042138 PMC: 10091246.

A case report of mucinous tubular and spindle cell carcinoma of the kidney.

Lundon D, Kelly B, Casby C, Coyle D, Flaherty R, Hynes S Am J Clin Exp Urol. 2023; 11(1):75-78.

PMID: 36923724 PMC: 10009310.

References

Kenney P, Vikram R, Prasad S, Tamboli P, Matin S, Wood C . Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. BJU Int. 2014; 116(1):85-92. DOI: 10.1111/bju.12992. View

MacLennan G, Farrow G, Bostwick D . Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology. 1997; 50(5):679-84. DOI: 10.1016/S0090-4295(97)00335-X. View

Koshkin V, Barata P, Zhang T, George D, Atkins M, Kelly W . Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018; 6(1):9. PMC: 5789686. DOI: 10.1186/s40425-018-0319-9. View

Larkin J, Fisher R, Pickering L, Thway K, Livni N, Fisher C . Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib. J Clin Oncol. 2010; 28(28):e539-40. DOI: 10.1200/JCO.2010.30.1457. View

Fuchizawa H, Kijima T, Takada-Owada A, Nagashima Y, Okazaki A, Yokoyama M . Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab. IJU Case Rep. 2021; 4(5):333-337. PMC: 8413205. DOI: 10.1002/iju5.12342. View

Uchida S, Suzuki K, Uno M, Nozaki F, Li C, Abe E . Mucin-poor and aggressive mucinous tubular and spindle cell carcinoma of the kidney: Two case reports. Mol Clin Oncol. 2017; 7(5):777-782. PMC: 5649005. DOI: 10.3892/mco.2017.1400. View

Zhao M, He X, Teng X . Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol. 2015; 10:168. PMC: 4573286. DOI: 10.1186/s13000-015-0402-1. View

Simon R, di SantAgnese P, Palapattu G, Singer E, Candelario G, Huang J . Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid differentiation. Int J Clin Exp Pathol. 2008; 1(2):180-4. PMC: 2480554. View

Shen S, Ro J, Tamboli P, Truong L, Zhai Q, Jung S . Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol. 2007; 11(1):13-21. DOI: 10.1016/j.anndiagpath.2006.09.005. View

10.

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

11.

Heng D, Xie W, Regan M, Harshman L, Bjarnason G, Vaishampayan U . External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14(2):141-8. PMC: 4144042. DOI: 10.1016/S1470-2045(12)70559-4. View

12.

Yoneyama S, Yumura Y, Koizumi M, Hanai T, Ishida H, Hattori Y . [Case of renal cell carcinoma with intertrabecular vertebral metastases detected f-18 fluorodeoxyglucose positron emission tomography and MRI]. Hinyokika Kiyo. 2014; 60(1):29-32. View

13.

Chahoud J, Msaouel P, Campbell M, Bathala T, Xiao L, Gao J . Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2020; 25(3):252-258. PMC: 7066696. DOI: 10.1634/theoncologist.2019-0372. View

14.

Bulimbasic S, Ljubanovic D, Sima R, Michal M, Hes O, Kuroda N . Aggressive high-grade mucinous tubular and spindle cell carcinoma. Hum Pathol. 2009; 40(6):906-7. DOI: 10.1016/j.humpath.2009.03.004. View

15.

Dhillon J, Amin M, Selbs E, Turi G, Paner G, Reuter V . Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol. 2008; 33(1):44-9. DOI: 10.1097/PAS.0b013e3181829ed5. View

16.

Fine S, Argani P, DeMarzo A, Delahunt B, Sebo T, Reuter V . Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney. Am J Surg Pathol. 2006; 30(12):1554-60. DOI: 10.1097/01.pas.0000213271.15221.e3. View

17.

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z . 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49(5):798-805. DOI: 10.1016/j.eururo.2005.11.035. View

18.

Pillay N, Ramdial P, Cooper K, Batuule D . Mucinous tubular and spindle cell carcinoma with aggressive histomorphology--a sarcomatoid variant. Hum Pathol. 2008; 39(6):966-9. DOI: 10.1016/j.humpath.2007.10.006. View

19.

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

20.

Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016; 70(1):93-105. DOI: 10.1016/j.eururo.2016.02.029. View